CSS
SNDX icon

Cubist Systematic Strategies’s Syndax Pharmaceuticals SNDX Stock Holding History

Cubist Systematic Strategies’s Portfolio SNDX Stock Details SNDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		$3.8M Buy
246,779
+70,749
+40% +$926K 0.02% 1143
2025
Q2 		$1.65M Buy
176,030
+175,630
+43,908% +$1.93M 0.01% 1665
2025
Q1 		$4.91K Sell
400
-357,671
-100% -$5.04M ﹤0.01% 2773
2024
Q4 		$4.73M Buy
+358,071
New +$6.13M 0.03% 871
2023
Q4 		– Sell
-192,094
Closed -$2.79M – 4074
2023
Q3 		$2.79M Buy
+192,094
New +$3.63M 0.02% 1128
2023
Q2 		– Sell
-7,920
Closed -$167K – 4248
2023
Q1 		$167K Buy
+7,920
New +$197K ﹤0.01% 3297
2022
Q2 		– Sell
-57,804
Closed -$1M – 4556
2022
Q1 		$1M Buy
57,804
+20,206
+54% +$340K 0.01% 2019
2021
Q4 		$823K Buy
37,598
+21,205
+129% +$392K 0.01% 2069
2021
Q3 		$313K Sell
16,393
-4,773
-23% -$79.5K ﹤0.01% 2330
2021
Q2 		$363K Buy
21,166
+4,415
+26% +$80.9K ﹤0.01% 2218
2021
Q1 		$375K Sell
16,751
-17,696
-51% -$400K ﹤0.01% 2122
2020
Q4 		$766K Buy
34,447
+26,747
+347% +$555K 0.01% 1543
2020
Q3 		$114K Sell
7,700
-7,761
-50% -$118K ﹤0.01% 2265
2020
Q2 		$229K Buy
+15,461
New +$235K ﹤0.01% 1974
2018
Q4 		– Sell
-2,144
Closed -$17K – 2263
2018
Q3 		$17K Buy
+2,144
New +$15.3K ﹤0.01% 1797
2017
Q2 		– Sell
-1,200
Closed -$16K – 1868
2017
Q1 		$16K Sell
1,200
-1,466
-55% -$15.2K ﹤0.01% 1557
2016
Q4 		$19K Buy
+2,666
New +$29.2K ﹤0.01% 1636

Other funds holding SNDX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return

Cubist Systematic Strategies's SNDX Position: Q3 2025 in Review

Cubist Systematic Strategies increased its Syndax Pharmaceuticals (SNDX) stake by 40% in Q3 2025, buying an estimated $926K and bringing the position to 246,779 shares worth $3.8M. The position accounts for 0.02% of the portfolio, ranked #1143.

Cubist Systematic Strategies first reported a position in SNDX in Q4 2016 and has held it in 17 quarters since. The position peaked at $4.73M in Q4 2024. 227 funds tracked by Wall St. Rank hold SNDX as of Q3 2025.

  • Cubist Systematic Strategies held 246,779 shares of Syndax Pharmaceuticals worth $3.8M as of Q3 2025.
  • Cubist Systematic Strategies bought 70,749 Syndax Pharmaceuticals shares in Q3 2025, an estimated $926K.
  • Syndax Pharmaceuticals made up 0.02% of Cubist Systematic Strategies's portfolio in Q3 2025, its #1143 holding.
  • Cubist Systematic Strategies first reported a position in Syndax Pharmaceuticals in Q4 2016 and has held it in 17 quarters since.
  • Cubist Systematic Strategies's Syndax Pharmaceuticals position peaked at $4.73M in Q4 2024.
  • 227 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q3 2025.

Based on Cubist Systematic Strategies's 13F filing for Q3 2025, filed 14 Nov 2025.